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Abstract
Hemoglobin beta (HBB):c.*+96T>C substitution is very rare among β-globin gene mutations and its 
clinical  significance  remains  to  be  clarified.  The  present  study  aimed  to  investigate  the  role  of 
HBB:c.*+96T>C in the β-thalassemia intermedia phenotype in a Turkish family. The proband and 
parents were screened for β-globin gene mutations via direct sequencing. Hematological and physical 
examination results were recorded, and correlated according to genotype. The proband was compound 
heterozygous for Cod 8 (-AA) and HBB:c.*+96T>C, whereas his mother and father were heterozy-
gous for Cod 8 (-AA) and HBB:c.*+96T>C, respectively. The father had almost normal hematological 
findings, whereas the mother had the typical β-thalassemia trait phenotype. The proband was diag-
nosed as mild β-thalassemia intermedia based on hepatosplenomegaly and hematological findings. To 
the best of our knowledge this is the first report of HBB:c.*+96T>C mutation in a Turkish family. 
HBB:c.* 96T>C substitution is a very rare, but clinically relevant β-globin gene mutation. Additionally, 
we think that if 1 spouse is a carrier for β-globin gene mutation the other should be screened for silent 
mutations, such as HBB:c.*+96T>C mutation of the β-globin gene, even if she/he does not have any 
clinical or hematological signs of the β-thalassemia trait phenotype. (Turk J Hematol 2011; 28: 219-22)
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Özet
Hemoglobin beta (HBB):c.*+96T>C, β-globin geninde çok nadir görülen ve klinik önemi henüz tam 
olarak aydınlatılamamış bir değişimdir. Bu çalışmada; bir Türk ailede HBB:c.*+96T>C değişiminin 
beta-talasemi intermedia fenotipi üzerine etkisini araştırmayı amaçladık. Beta-talasemi intermedia ön 
tanılı çocuk ile anne ve babasının β-globin gen mutasyonları DNA dizi analizi yöntemiyle tarandı. Aile 
bireylerinin hematolojik ve klinik bulguları elde edilerek, genotipleri ile birlikte değerlendirildi. Direkt Introduction
β-thalassemia  is  a  hereditary  blood  disorder 
characterized  by  anomalies  in  hemoglobin  (Hb) 
beta-chain  synthesis  and  is  the  most  frequently 
observed  genetic  condition  in  the  world  [1]. 
Diagnosis of β-thalassemia is based on hematologic 
and  molecular  genetic  test  results  [2].  To  date, 
more than 200 mutations have been reported; the 
disease exhibits a high level of molecular and clini-
cal heterogeneity [3,4]. Among β-globin gene muta-
tions,  HBB:c.25_26delAA  (Cod  8  [-AA]),  which 
results  in  frame  shift  and  stop  codon  at  the  21st 
amino acid, is a rare mutation with an incidence of 
2.1% among all β-globin gene mutations in Antalya 
Province [5]. HBB:c.*+96T>C or 3’UTR+1570 T>C 
is  a  very  rare  mutation  located  12  nucleotides 
upstream of the polyadenylation signal in 3’ UTR of 
the β-globin gene. There are a limited number of 
reports  on  the  prevalence  and  clinical  role  of 
HBB:c.*+96T>C [6]. Additionally, there is a lack of 
consensus  concerning  the  clinical  importance  of 
HBB:c.*+96T>C. To the best of our knowledge the 
present study is the first to report HBB:c.*+96T>C 
substitution in Turkey. The present study aimed to 
investigate  the  effect  of  the  co-existence  Cod  8 
(-AA)  and  HBB:c.*+96T>C  substitution  on  mild-
type β-thalassemia intermedia in a Turkish family.
Materials and Methods
The  proband,  with  ultrasound  findings  of 
hepatomegaly  and  splenomegaly,  and  unusual 
blood  parameters,  and  his  parents  were  referred 
from the hematology department to our laboratory 
for screening of β-globin gene mutations. The fami-
ly’s hematological findings were recorded. Informed 
consent was obtained from all the family members. 
Following  genomic  DNA  extraction  from  whole 
blood  using  the  salting-out  method  [7],  genomic 
DNA was measured using a NanoDrop 1000 spec-
trophotometer (Thermo Scientific, Wilmington, DE, 
USA). The proband and his parents were screened 
via direct sequencing of the region including 5’ UTR 
(-101 position) of the β-globin to 3’ UTR (Poly-A sig-
nal)  in  the  β-globin  gene.  Sequencing  was  per-
formed  using  a  BigDye  Terminator  v3.1  Cycle 
Sequencing kit and an ABI prism 3130 genetic ana-
lyzer (Applied-Biosystems, Foster City, CA).
Results
Clinical  examination  showed  that  the  proband 
had hepatomegaly with a longitudinal measure of 
167  mm  (normal:  <155  mm)  and  splenomegaly 
with a longitudinal measure of 172 mm (normal: 
<130 mm), based on abdominal ultrasound find-
ings.  Hematological  findings  for  the  proband  and 
parents  are  given  in the  Table. The  proband  was 
compound heterozygous for HBB:c.*+96T>C and 
Cod 8 (-AA) mutations according to DNA sequenc-
ing. His mother was a carrier of the Cod 8 (-AA) 
mutation,  and  his  father  was  a  carrier  of  the 
HBB:c.*+96T>C mutation. β-globin DNA sequenc-
ing showed HBB:c.*+96T>C and Cod 8 (-AA) muta-
tions in the proband (Figure). 
Following  clinical  and  hematological  examina-
tions,  the  proband  was  diagnosed  as  mild  type 
β-thalassemia  intermedia.  Although  the  patient’s 
MCH level was low (18.60 pg/cell), his Hb level (11.5 
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DNA dizi analizi yöntemiyle mutasyon taranması sonucunda, olgunun Cod 8 (-AA) ve HBB:c.*+96T>C 
mutasyonları açısından birleşik heterozigot olduğu belirlendi. Annenin Cod 8 (-AA) mutasyonu, baba-
nın ise HBB:c.*+96T>C mutasyonu yönünden taşıyıcı oldukları görüldü. Anne klasik beta-talasemi 
taşıyıcı bulgularına sahip iken, babanın klinik ve hematolojik açıdan normale yakın olduğu belirlendi. 
Diğer yandan olgu, hematoloji bulgularına ek olarak, hepato-splenomegalinin varlığı ile ılımlı tip beta-
talasemi intermedia tanısı aldı. Bu çalışmada, HBB:c.*+96T>C değişimi ilk kez bir Türk ailesinde 
bildirilmektedir.  Cod  8  (-AA)  ve  HBB:c.*+96T>C  değişimleri  açısından  birlikte  heterozigot  olan 
olguda, sadece Cod 8 (-AA) mutasyonu ile açıklanamayacak klinik bulguların gözlenmesi nedeniyle, 
HBB:c.*+96T>C’ nın taşıyıcılarda sessiz, ancak başka bir mutasyonla birlikte olduğunda hastalık 
şiddetini artıran, klinik açıdan önemli bir β-globin geni mutasyonu olduğu sonucuna varıldı. Ayrıca, 
çiftlerden birinin taşıyıcılığının genetik testlerle kesinleştiği durumlarda, diğerinin klinik ve hematolo-
jik  olarak  taşıyıcı  bulgularına  sahip  olmasa  bile,  HBB:c.*+96T>C  gibi  hematolojik  açıdan  sessiz 
mutasyonlar için taranması gerektiğini önermekteyiz. (Turk J Hematol 2011; 28: 219-22)
Anahtar kelimeler: Ilımlı tip beta-talasemi intermedia, Beta-globin geni, HBB:c.*+96T>C
Geliş tarihi: 23 Ekim 2010    Kabul tarihi: 12 Ocak 2011g/dL) was compensated by an elevated RBC count 
(6.16  million  mm3).  The  proband’s  mother  had 
hematological findings that correlated with the β-tha-
lassemia trait due to Cod 8 (-AA) mutation, whereas 
the father (who only had the HBB:c.*+96T>C muta-
tion) did not have hematological findings associated 
with the β-thalassemia trait.
Discussion
β-thalassemia  due  to  structurally  abnormal 
hemoglobin or an insufficient quantity of Hb is the 
most common genetic disease with a wide spec-
trum of phenotypic heterogeneity caused by genetic 
variation. The modifier factors that play in the sever-
ity of β-thalassemia are not well known. Cod 8 (-AA) 
is a frame shift mutation that creates a stop codon at 
the 21st codon, leading to β0-thalassemia. The modi-
fied C-terminal amino acid sequence in the β-globin 
gene with Cod 8 (-AA) mutation is as follows: (8)Val-
Cys-Arg-Tyr-Cys-Pro-Val-Gly-Gln-Gly-Glu-Arg-(20)Gly-
COOH  (http://globin.bx.psu.edu/cgi-bin/hbvar/
query_vars3). On the other hand, Cai et al. reported 
that HBB:c.*+96T>C was the only genomic altera-
tion responsible for the β-thalassemia trait phenotype 
with elevated HbA2 levels in 5 members of an Irish 
family. They also reported that the β-thalassemia trait 
phenotype in the family was caused by the known 
mutation IVS-II-654 C>T [8,9]. Additionally, Divoky et 
al. reported that HBB:c.*+96T>C was not associated 
with  β-thalassemia  phenotypes  in  Czech  patients 
and that HBB:c.*+96T>C is linked to IVS-II-654 C>T 
mutation [6]. We examined our sequence results for 
such a mutation, but IVS-II-654 C>T mutation was 
not present in the presented family. Giambona et al. 
reported  HBB:c.*+96T>C  mutation  in  an  Italian 
patient  with  a  slightly  elevated  HbA2  level  [10]. 
Moreover,  Boussiou  et  al.  observed  the 
HBB:c.*+96T>C mutation in 7 Greek patients with-
out any clinical symptoms [11]. 
The presented proband had compound hetero-
zygosity  for  Cod  8  (-AA)  mutation  and 
HBB:c.*+96T>C, and had clinical and hematologi-
cal  findings  associated  with  mild  β-thalassemia 
intermedia, whereas his mother had some findings 
indicative of anemia, such as paleness and fatigue, 
in addition to hematological parameters consistent 
with the trait phenotype due to Cod 8 (-AA) muta-
tion (she occasionally takes folic acid and zinc tab-
lets). Compared to the mother’s blood parameters, 
the proband’s Hb (11.5 g/dL), MCV (59.9 fL), and 
MCH  (18.6  pg/cell)  levels  were  lower,  and  RBC 
(6.16×1012 mm3), HbA2 (5.65%), and HbF (2.20%) 
levels were higher (Table 1). On the other hand, the 
proband’s  father  was  clinically  normal,  despite 
being a carrier of the HBB:c.*+96T>C mutation. 
The father’s laboratory tests did not show any sig-
nificant hematological findings that could be due to 
HBB:c.*+96T>C  mutation  other  than  a  slightly 
reduced RBC count (4.0×1012 mm3) and Hb level 
(12.9 g/dL). This implies that HBB:c.*+96T>C carri-
ers might be hematologically asymptomatic. Although 
by itself HBB:c.*+96T>C mutation does not cause 
the β-thalassemia trait phenotype in carriers, it prob-
ably  has  an  additive  affect  when  it  co-exists  with 
other β-globin gene mutations such as Cod 8 (-AA).
It was suggested that T>C substitution at posi-
tion +1570 in the β-globin gene (12 bp upstream of 
the AATAAA polyadenylation signal) may contribute 
to  the  β-thalassemia  phenotype  by  destabilizing 
β-globin  mRNA  [12].  Destabilization  of  mRNA 
processing due to HBB:c.*+96T>C mutation togeth-
er with Cod 8 (-AA) mutation may have resulted in 
Figure 1. T>C transition at the c.*+96 position (left) and the frame shift 
mutation Cod 8 (-AA) (right) detected via DNA sequencing in the proband
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Table 1. Hematological and molecular findings in the family members
  Age/   β-globin gene  RBC  Hb  MCV  MCH  MCHC  HbA2  HbF
  gender  mutation(s)  (mm3)   (g/dL)   (fL)   (pg/cell)   (g/dL)  (%)  (%)
Proband  20/M  Cod 8 (-AA)/ HBB:c.*+96T>C  6.16  11.5  59.9  18.60  31.1  5.65  2.20
Father  59/M  HBB:c.*+96T>C  4.00  12.9  92.60  32.30  34.9  2.20  0.20
Mother  49/F  Cod 8 (-AA)  6.14  12.5  61.9  20.30  32.8  4.40  0.30the mild β-thalassemia intermedia phenotype in the 
presented  proband,  as  patients  that  are  hetero-
zygous for the Cod 8 (-AA) mutation do not have the 
mild  β-thalassemia  intermedia  phenotype  with 
hepatosplenomegaly.  As  such,  we  think  that  the 
combination of β-globin gene mutations is impor-
tant  for  the  expression  of  the  mild  β-thalassemia 
intermedia phenotype.  
To the best of our knowledge the present study is 
the first to report the combination of HBB:c.*+96T>C 
and Cod 8 (-AA). In addition, based on the very low 
frequency  of  HBB:c.*+96T>C  substitution  in  the 
thousands of patients that have been sequenced in 
our laboratory, as well as in other laboratories, it 
can be considered a clinically important mutation 
that  causes  mild  β-thalassemia.  More  detailed 
molecular studies on other factors, such as mRNA 
instability and other globin genes, should be per-
formed to further clarify the role of HBB:c.*+96T>C 
mutation in the β-thalassemia trait phenotype.
In conclusion, we think that if 1 spouse is a car-
rier of a β-globin gene mutation, the other should be 
screened for silent mutations of the β-globin gene, 
even if she/he does not have any clinical or hema-
tological signs of the β-thalassemia trait phenotype. 
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